Jagsonpal Pharmaceuticals Q1FY26 Results: PAT Doubles to ₹108 Mn on Strong Revenue Growth
By HDFC SKY | Published at: Jul 26, 2025 07:39 PM IST
Gurugram, July 26, 2025 – Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) reported a strong start to FY26, with its unaudited financial results for the quarter ended June 30, 2025, showcasing double-digit revenue growth, significant improvement in profitability, and robust cash generation.
Q1FY26 Financial Highlights
| Particulars | Q1FY26 | Q1FY25 | YoY Change | Q4FY25 | QoQ Change |
|---|---|---|---|---|---|
| Revenue from Operations (₹ Mn) | 756 | 614 | +23.1% | 586 | +29.1% |
| Operating EBITDA (Pre-ESOP) (₹ Mn) | 157 | 127 | +24.1% | 97 | +61.9% |
| EBITDA Margin (Pre-ESOP) | 20.8% | 20.6% | +17 bps | 16.6% | +420 bps |
| Net Profit (PAT) (₹ Mn) | 108 | 53 | +102.8% | 66 | +63.5% |
| PAT Margin | 14.3% | 8.7% | +562 bps | 11.3% | +300 bps |
Note: EBITDA margins are calculated before ESOP costs.
Gross margin improved by 80 bps YoY to 64.4%.
Operational Strength
- Cash Position: Free cash flow of ₹153 Mn added during the quarter, increasing total cash reserves to ₹1,609 Mn as of June 30, 2025.
- Brand Momentum: The company reinforced its position as #7 in the Gynaecology CVM rankings and maintained leadership across orthopaedics and paediatrics.
- Asset-Light Model: Continued reliance on outsourced R&D and contract manufacturing ensured scalability without capital strain.
Segment-Wise Strategy
According to the company’s update:
- Gynaecology: Reaches ~90% of India’s gynaecologists (35,000 out of 39,000) with leading presence in the progesterone segment.
- Orthopaedics: Covers 10,000 of 13,000 orthopaedic specialists with strong foothold in osteoporosis and osteoarthritis.
- Paediatrics and Dermatology: Maintains consistent medical engagement in gut health, dermatological care, and anti-infectives.
Management Commentary
Manish Gupta, Managing Director, stated:
“We have started FY26 on a strong note with growth across all parameters. Net profit more than doubled, and we added ₹153 Mn in free cash. We further strengthened our leadership in the Gynae CVM segment. Going forward, we will continue to explore inorganic growth opportunities backed by our strong cash position.”
Balance Sheet Overview
| Key Metrics | 30-Jun-25 (₹ Mn) | 31-Mar-25 (₹ Mn) | QoQ Change |
|---|---|---|---|
| Shareholders’ Funds | 2,535 | 2,399 | +5.7% |
| Cash & Equivalents | 1,609 | 1,456 | +10.5% |
| Intangible Assets | 837 | 856 | -2.2% |
| Net Working Capital | 99 | 93 | +5.5% |
Strategic Outlook
Jagsonpal is targeting:
- FY26 Revenue Growth: 15%+
- Operating EBITDA Improvement: 20%+
- Post-FY26 Growth: 12–14% revenue CAGR with 100–150 bps margin expansion
The company also continues to explore inorganic acquisitions in current and adjacent therapeutic categories to accelerate growth.
About the Company
Jagsonpal Pharmaceuticals is a Delhi-headquartered pharma player with over four decades in the Indian market. It focuses on branded generics across gynaecology, orthopaedics, paediatrics, and dermatology. The company is listed on NSE (JAGSNPHARM) and BSE (507789) and operates with an asset-light, cash-rich model supported by over 1,000 medical representatives nationwide.
For more details, visit www.jagsonpal.com.
REF: https://nsearchives.nseindia.com/corporate/JAGSNPHARM_26072025170257_Investors_presntation_F.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
